A recent medical trial could help deliver the first daily weight loss pill capable of cutting down obesity as effectively as ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

With the growing popularity of weight loss medications, many people are turning to prescription options to help them achieve their health goals. Medications like Ozempic, Mounjaro, and Wegovy are ...

Novo Nordisk submitted an oral version of the weight-loss formulation of semaglutide (Wegovy) for FDA approval, according to ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

Ozempic made headlines thanks to social media and publicity from celebrities and influencers who swore by its effects on ...